Compare MiniMed Group Inc. Common Stock (MMED) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MiniMed Group Inc. Common Stock vs Travere Therapeutics Inc. Common Stock — how do they compare? MiniMed Group Inc. Common Stock trades at $16.74 (market cap $5.18B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: MiniMed Group Inc. Common Stock and Travere Therapeutics Inc. Common Stock are close in size by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, MiniMed Group Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold MiniMed Group Inc. Common Stock for 6 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MMED | TVTX | |
|---|---|---|
Market Cap | $5.18B | $4.88B |
Volume | 33,606,669 | 1,668,577 |
Sector | Health | Health |
52-Week High | $23.84 | $67.52 |
52-Week Low | $10.80 | $26.79 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $4.98B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MMED trades at $18.40, down 2.13% today, with technical indicators showing bearish momentum. The company reported revenue growth to $2.72B in 2025 but posted a net loss of -$250M. Recent news highlights Medtronic's exchange offer completion and MiniMed's new product launches. Analyst consensus remains strongly bullish with 100% buy ratings and a $25.73 price target, representing 40% upside potential from current levels.
Despite negative profitability metrics and bearish technical signals, MMED maintains strong analyst support and revenue growth trajectory. Key risks include persistent net losses, high short interest, and execution challenges in the competitive diabetes technology market. The stock offers potential upside if new product cycles drive margin improvement and profitability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MiniMed Group Inc. Common Stock
MiniMed develops, manufactures, and markets diabetes-management technologies. Its products include insulin-delivery systems, continuous glucose monitors, smart insulin pens, and related software.
Read more on MMED →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
